On July 10, 2025, MIRA Pharmaceuticals reported promising preclinical results for SKNY-1, an oral drug candidate, showing a reversal of anxiety-related behaviors in animal models, while also demonstrating potential for significant weight loss and effects on nicotine addiction. The company is preparing for shareholder approval to acquire SKNY Pharmaceuticals, pending which they plan to start IND-enabling studies for SKNY-1.